Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 282

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

Open access
Ahmadzadehfar, Hojjat, Eppard, Elisabeth, Kürpig, Stefan, Fimmers, Rolf, Yordanova, Anna, Schlenkhoff, Carl Diedrich, Gärtner, Florian, Rogenhofer, Sebastian, Essler, Markus·2016·Oncotarget

Abstract

// Hojjat Ahmadzadehfar 1 , Elisabeth Eppard 1 , Stefan Kürpig 1 , Rolf Fimmers 2 , Anna Yordanova 1 , Carl Diedrich Schlenkhoff 1 , Florian Gärtner 1 , Sebastian Rogenhofer 3 , Markus Essler 1 1 Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany 2 Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany 3 Department of Urology, University Hospital Bonn, Bonn, Germany Correspondence to: Hojjat Ahmadzadehfar, e-mail: Hojjat.ahmadzadehfar@ukb.uni-bonn.de , nuclearmedicine@gmail.com Keywords: PSMA, 177 Lu, prostate cancer, radioligand therapy, PSA Received: October 26, 2015 Accepted: January 27, 2016 Published: February 08, 2016 ABSTRACT Prostate-specific membrane antigen (PSMA) is highly expressed on prostate epithelial cells and strongly up-regulated in prostate cancer (PC), making it an optimal target for the treatment of metastasized PC. Radioligand therapy (RLT) with 177 Lu-PSMA-DKFZ-617 (Lu-PSMA) is a targeted therapy for metastatic PC. In this study, we retrospectively analyzed the side effects and the response rate of 24 hormone and/or chemorefractory PC patients with a mean age of 75.2 years (range: 64–82) with distant metastases and progressive disease according to the PSA level, who were treated with Lu-PSMA. Median PSA was 522 ng/ml (range: 17–2360). Forty-six cycles of Lu-PSMA were performed. Of the 24 patients, 22 received two cycles. Eight weeks after the first cycle of Lu-PSMA therapy 79.1% experienced a decline in PSA level. Eight weeks after the second cycle of Lu-PSMA therapy 68.2% experienced a decline in PSA relative to the baseline value. Apart from two cases of grade 3 anemia, there was no relevant hemato- or nephrotoxicity (grade 3 or 4). These results confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile. A positive response to therapy in terms of decline in PSA occurs in about 70% of patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.7245

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 282

Metadata

Authors
Ahmadzadehfar, H., Eppard, E., Kürpig, S., Fimmers, R., Yordanova, A., Schlenkhoff, C. D., Gärtner, F., Rogenhofer, S., & Essler, M.
Venue
Oncotarget
Published
2016-02-08
Volume
7
Issue
11
Pages
12477-12488
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2302508993
Cited by
282
References
19
FWCI
36.27
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.